These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 38786085)

  • 1. Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.
    Ho M; Bonavida B
    Cells; 2024 May; 13(10):. PubMed ID: 38786085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
    Hays E; Bonavida B
    Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
    Hack SP; Zhu AX; Wang Y
    Front Immunol; 2020; 11():598877. PubMed ID: 33250900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; CaƱete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer.
    Wottrich S; Kaufhold S; Chrysos E; Zoras O; Baritaki S; Bonavida B
    Drug Resist Updat; 2017 Jan; 30():28-38. PubMed ID: 28363333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1.
    Ibrahim AA; Fujimura T; Uno T; Terada T; Hirano KI; Hosokawa H; Ohta A; Miyata T; Ando K; Yahata T
    Front Immunol; 2024; 15():1365894. PubMed ID: 38779680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics.
    Wang Y; Bonavida B
    Crit Rev Oncog; 2018; 23(5-6):281-305. PubMed ID: 30311561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
    Hudson K; Cross N; Jordan-Mahy N; Leyland R
    Front Immunol; 2020; 11():568931. PubMed ID: 33193345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy.
    Sun J; Lu Q; Sanmamed MF; Wang J
    Clin Cancer Res; 2021 Feb; 27(3):680-688. PubMed ID: 32958700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation.
    Baritaki S; Katsman A; Chatterjee D; Yeung KC; Spandidos DA; Bonavida B
    J Immunol; 2007 Oct; 179(8):5441-53. PubMed ID: 17911631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
    Kalantari Khandani N; Ghahremanloo A; Hashemy SI
    J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1.
    Dillen A; Bui I; Jung M; Agioti S; Zaravinos A; Bonavida B
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
    Lu C; Paschall AV; Shi H; Savage N; Waller JL; Sabbatini ME; Oberlies NH; Pearce C; Liu K
    J Natl Cancer Inst; 2017 Jan; 109(6):. PubMed ID: 28131992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma.
    Shvartsur A; Givechian KB; Garban H; Bonavida B
    J Exp Clin Cancer Res; 2017 May; 36(1):62. PubMed ID: 28476134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.